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Abstract
Background: The etiology of type 1 diabetes mellitus (T1DM) is still unknown; numerous studies are performed to unravel
the environmental factors involved in triggering the disease. SLC11A1 is a membrane transporter that is expressed in late
endosomes of antigen presenting cells involved in the immunopathogenic events leading to T1DM. Mycobacterium avium
subsp. paratuberculosis (MAP) has been reported to be a possible trigger in the development of T1DM.
Methodology/Principal Findings: Fifty nine T1DM patients and 79 healthy controls were genotyped for 9 polymorphisms
of SLC11A1 gene, and screened for the presence of MAP by PCR. Differences in genotype frequency were evaluated for both
T1DM patients and controls. We found a polymorphism in the SLC11A1 gene (274C/T) associated to type 1 diabetic patients
and not to controls. The presence of MAP DNA was also significantly associated with T1DM patients and not with controls.
Conclusions/Significance: The 274C/T SCL11A1 polymorphism was found to be associated with T1DM as well as the
presence of MAP DNA in blood. Since MAP persists within macrophages and it is also processed by dendritic cells, further
studies are necessary to evaluate if mutant forms of SLC11A1 alter the processing or presentation of MAP antigens
triggering thereby an autoimmune response in T1DM patients.
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Introduction
Type 1 diabetes mellitus (T1DM) is a multifactorial autoimmune
disease in which T-lymphocytes infiltrate the islets of the pancreas
and destroy the insulin-producing beta cell populations [1]. The
exact cause of T1DM is not clearly known. However T1DM
constitutes interactions of polygenic traits with environmental
factors that are not clearly defined in the available literature and
it is not known what triggers autoimmunity to self-antigens such as
those expressed in the pancreatic islets of Langerhans cells [2,3].
Accumulating line of evidence points to role for Mycobacterium
avium subsp. paratuberculosis (MAP) in the development of T1DM as
an environmental trigger [2,4,5]. MAP bacteria have been
generally known to harness molecular mimicry as a strategy to
avoid clearance [6]. Recently our group observed immune
responses to MAP in T1DM patients, thus supporting an
infectious cause for T1DM [7]. Moreover, the presence of MAP
was confirmed in T1DM patients by culture and was isolated from
blood of T1DM patients [4]. It has long been held that genetic
susceptibilities, epitope homologies, and endemic bacterial load in
the environment might support the case for an infectious trigger,
such as MAP, to be the probable agent of T1DM in genetically
susceptibility individuals [3,8,9,10].
Regarding genetic susceptibility, the SLC11A1 gene (previously
known as NRAMP1) is a functional and a positional candidate gene
that associates with T1DM as well as susceptibility to mycobac-
terial infections [11,12,13,14]. Additionally, Kissler et al. [15]
demonstrated that SLC11A1 gene silencing using RNAi approach
in mice reduced the frequency of T1DM and protected against
experimental autoimmune encephalomyelitis, advocating thereby
for a role for SLC11A1 in autoimmunity. Moreover, it was recently
demonstrated that association of variants of the gene encoding
SLC11A1 with T1DM may reflect its function in processing and
presentation of islet cell self-antigens to dendritic cells (DCs) [16].
Thus, non-MHC genes could affect the MHC-restricted T-cell
response through altered antigen processing and presentation.
To date, a number of polymorphisms at the SLC11A1 locus
have been associated with susceptibility to infectious agents and
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polymorphism in the promoter region of the SLC11A1 gene seems
to be of particular interest, since it has been shown to affect the
levels of gene expression [17]. In vitro studies of this polymorphism
suggested direct contribution of particular alleles either to
autoimmune (allele 3) or to infectious (allele 2) disease suscepti-
bility [10,17]. Nevertheless, variants of the SLC11A1 located within
the coding region, the introns, and the 39-UTR have been shown
to influence susceptibility to autoimmune disorders and T1DM
[13,18].
Our study aimed at examining the association of the SLC11A1
polymorphisms in relation to the presence of MAP infection, with
T1DM in patients from Sardinia.
Methods
Patients and controls
A total of 131 participants comprising of 59 T1DM patients (28
females and 31 males with age ranging between 18–94 years) and
76 healthy controls (Table 1) were tested for the detection of
SLC11A1 polymorphisms and the presence of MAP specific IS900
signature using total DNA extracted from peripheral blood
mononuclear cells collected at the Institute of Diabetology,
medical clinic of Sassari University, Italy. Informed written
consents from patients including other necessary clearances were
obtained before blood samples were drawn. Institutional review
board of the University of Sassari approved the study.
Briefly, 5 ml blood from patients was centrifuged and plasma
supernatant used in ELISA. Remaining plasma samples were
aliquoted and stored frozen at 220uC for short-term storage (,6
months) and 280uC for long term storage (.6 months).
DNA extraction
To extract MAP DNA, samples were processed by using the
lysor instrument - 500 ml of glass beads (Sigma) were added,
followed by standard phenol-chloroform extraction and DNA
precipitation with absolute ethanol and 10M ammonium acetate;
the pellet was washed with 70% ethanol and resuspended in 70 ml
of TE buffer.
Human genomic DNA extraction for SCL11A1 gene amplifica-
tion was performed as previously published [14].
MAP DNA detection
MAP DNA detection was performed by PCR as previously
reported [14,19]. Sequence analysis of the amplicons confirmed
IS900 identity. For SCL11A1 polymorphisms, 100 ng of template
(genomic) DNA, obtained from blood cells, was amplified. The
primer sequences and PCR cycling parameters that we used were
previously reported [5].
SLC11A1 genotyping
Nine polymorphisms (-274C/T, D543N G/A, 823C/T,
-237C/T, INT4G/C, 577-18G/A, A318V C/T, 1465-85G/A,
and 1729+55del4) were genotyped across NRAMP1 [14].
Candidates were genotyped across these polymorphisms by
PCR restriction fragment length polymorphism (PCR-RFLP), in
which primers and restriction enzymes were used as previously
described [14]. Restriction enzyme digestion products were
resolved by electrophoresis on 3% agarose gels stained with
ethidium bromide.
Statistical analysis was performed by using the Chi square test
with Yate’s correction. Inference was aided by GraphPad InStat
(version 3.00, GraphPad Software, Inc., San Diego, CA, USA)
Table 1. Presence of MAP and SLC11A1 genotypic






MAP** present 33 18
not present 26 61 ,0.0005
274 C/T Allele 1 12 35
Allele 2 28 30
Allele 1 & 2 19 7 ,0.0005
No product 0 7
469+14G/C Allele 1 30 36
Allele 2 2 3
Allele 1 & 2 3 15 0.065
No product 24 25
577-18G/A Allele 1 0 4
Allele 2 59 72
Allele 1 & 2 0 0 0.131
No product 0 3
823C/T Allele 1 0 0
Allele 2 44 69
Allele 1 & 2 0 1 1.000
No product 15 9
A318V Allele 1 0 2
Allele 2 40 46
Allele 1 & 2 0 0 0.498
No product 19 31
1465-85G/A Allele 1 25 35
Allele 2 20 16
Allele 1 & 2 13 8 0.196
No product 1 20
D543N avaII Allele 1 1 1
Allele 2 57 68
Allele 1 & 2 1 0 0.730
No product 0 10
D543N fokI Allele 1 46 59
Allele 2 0 1 0.9517
Allele 1 & 2 0 0
No product 13 19
1729+55del4 Allele 1 59 46
Allele 2 0 0
Allele 1 2 0 0 1.000
No product 0 33
(Gt)n Allele 3 31 21 0.5983
Allele 2 9 9
Altro 3*/2* 6 8 0.5912
no product 13 41
*Fisher’s exact test;
**MAP = Mycobacterium avium subspecies paratuberculosis.
No product= no amplification obtained.
doi:10.1371/journal.pone.0007109.t001
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MAP detection
MAP DNA was amplified from the blood of 33 out of 59 T1DM
patients (55.9%) whereas MAP was detected only in 18 out of 79
healthy controls (22.7%) indicating a statistically highly significant
difference (Table 1).
SLC11A1 allele frequencies
SLC11A1 allele frequencies for 274 C/T polymorphism differed
significantly between T1DM patients and control group, this
polymorphism was significantly associated with diabetes type 1, in
particular allele 1 and 2 generated a P value of ,0.0005 (Table 1).
There was no significant difference in the allele frequencies of
the other 8 polymorphisms for 823 G/T, 577-18G/A, A318V and
1465-85G between T1DM patients and control group (Table 1).
Bivariate and multivariate logistic regression analysis was very
significant both for the presence of MAP and SLC11A1 274C/T
genotype to predict diabetes status among patients with T1DM
and non-diabetic controls as shown in Table 2. In particular, allele
2 alone showed an odds ratio of 2.7 (1.2, 6.3) in a bivariate model
and 2.7 (1.2, 6.3) in a multivariate model whereas allele 1 showed
an odds ratio of 7.9 (2.7, 23.5) in a bivariate model and 9.4 (2.9,
30.3) in a multivariate model.
Discussion
SLC11A1 gene has a vital function in the pathway of
macrophage activation [20]. It is involved in the expression of
chemokines, interleukin-1b, inducible nitric oxide synthase, MCH
II molecules, and TNF-a [17,21]. The localization of SLC11A1 is
within the late endosomal/lysosomal compartments in phagocytes
and it has been hypothesised to perform a transporter function as a
divalent cation [20,22]. Recent reports show a role of the SLC11A1
gene in different autoimmune diseases such as Crohn’s disease
[23], rheumatoid arthritis and juvenile rheumatoid arthritis
[24,25] multiple sclerosis [26], diabetes type 1 [18] and infectious
diseases including tuberculosis [27,28,29] and leprosy [30,31].
There is evidence that SLC11A1 gene is involved in modifying
susceptibility to T1DM as shown by RNA silencing that inversely
correlated with increased susceptibility to infection [13].
Antigen presenting cells have long been considered associated to
diabetes susceptibility [32,33] due to their exclusive expression of
MHC class II molecules, the major genetic factors underlying
T1DM. Different workers have identified diabetes-associated
genes that are also involved in antigen-processing pathways
[8,34]. SLC11A1 functions as a membrane transporter of divalent
cations but its mechanism of mediating natural resistance to
bacterial and parasitic infections remains unclear [17,22]. Previous
studies on the innate response of macrophages during intracellular
bacterial infection suggested that SLC11A1-mediated deprivation
of divalent cations might change the phagosomal microenviron-
ment that impairs the pathogenesis of intracellular pathogens [20].
Dai et al. found that SLC11A1 contributes to enhanced
phagosomal acidification in macrophages and dendritic cells
[16]. Based on these data, Dai et al. [16] suggest that SLC11A1-
mediated changes in antigen processing within the vesicular system
may have general effects in autoimmune as well as in infectious
diseases.
MAP is the causative agent of Johne’s disease in ruminants [35]
and it has been associated with Crohn’s disease [35,36]. We have
previously reported the presence of MAP DNA in the PBMC of
T1DM patients [5]. These finding were confirmed by detecting
MAP specific antibodies in the blood of T1DM patients but not in
type 2 diabetic patients and controls [19]. More recently two MAP
strains were isolated from the blood of T1DM patients by our
group [4].
In this study we report the novel association of T1DM with the
274 C/T polymorphism within the SLC11A1 gene and the
presence of MAP DNA in Sardinian T1DM patients. This
polymorphism may be the link of a permissive infection by MAP in
these people. Recent studies have reported that the 4-bp TGTG
deletion located 55 nucleotides downstream of the last codon in
exon 15 (1729 +del55del4) is associated with tuberculosis
susceptibility in Chinese children [29]. We did not find any
statistical difference at this locus between T1DM and healthy
controls. SCLA11 polymorphisms were analyzed also by stratifica-
tion by sex and no differences were observed (data not shown). It
may be possible that polymorphisms in different loci of the
SCL11A1 gene may confer susceptibility to different intracellular
pathogens although genetically very close. Further studies are
necessary in order to elucidate the role of SCL11A1 polymorphisms
and how it may influence MAP infection in humans.
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